Here's what most miss about GSK's China deal: it's a strategic play for early-stage R&D assets, not...

Here's what most miss about GSK's China deal: it's a strategic play for early-stage R&D assets, not just market access. GSK trades rights for Sino Biopharma's pipeline, highlighting how global pharma values external innovation.

For Indian biotechs, this signals that strong, novel R&D is a powerful currency for global partnerships, even for market entry elsewhere. Focus on your pipeline.

https://pharma.economictimes.indiatimes.com/news/pharma-industry/gsk-out-licenses-hepatitis-b-drug-china-rights-to-sino-biopharma/131010546